ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 2, 2012, Pages 306-317

  Gromova, Petra ^a   Rubin, Brian P ^b   Thys, An ^a   Cullus, Pierre ^a   Erneux, Christophe ^a   Vanderwinden, Jean Marie ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

ENDOGLIN; Gastrointestinal stromal tumour; Interstitial cells of Cajal; KIT

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CD31 ANTIGEN; CD34 ANTIGEN; CELL SURFACE RECEPTOR; DRUG DERIVATIVE; ENG PROTEIN, HUMAN; IMATINIB; LEUKOCYTE ANTIGEN; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ANIMAL; ARTICLE; DNA METHYLATION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INTERSTITIAL CELL OF CAJAL; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD31; ANTIGENS, CD34; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; ENDOTHELIUM, VASCULAR; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERSTITIAL CELLS OF CAJAL; MICE; MICE, TRANSGENIC; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

MUS;

EID: 84856332925     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01315.x     Document Type: Article

References (34)

1. Dallas NA, Samuel S, Xia L, et al Endoglin (CD105): a marker of tumour vasculature and potential target for therapy. Clin Cancer Res. 2008; 14: 1931-7.
2. Bellon T, Corbi A, Lastres P, et al Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol. 1993; 23: 2340-5.
3. Perez-Gomez E, Eleno N, Lopez-Novoa JM, et al Characterization of murine S-endoglin isoform and its effects on tumour development. Oncogene. 2005; 24: 4450-61.
4. Hawinkels LJ, Kuiper P, Wiercinska E, et al Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumour angiogenesis. Cancer Res. 2010; 70: 4141-50.
5. Levine RJ, Lam C, Qian C, et al Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355: 992-1005.
6. Venkatesha S, Toporsian M, Lam C, et al Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12: 642-9.
7. Li C, Gardy R, Seon BK, et al Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003; 88: 1424-31.
8. Li C, Guo B, Wilson PB, et al Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 2000; 89: 122-6.
9. Takahashi N, Kawanishi-Tabata R, Haba A, et al Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumours, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001; 7: 524-32.
10. Mysliwiec P, Pawlak K, Bandurski R, et al Soluble angiogenesis markers in gastric tumour patients. Folia Histochem Cytobiol. 2009; 47: 81-6.
11. Mysliwiec P, Pawlak K, Kuklinski A, et al Combined perioperative plasma endoglin and VEGF-a assessment in colorectal cancer patients. Folia Histochem Cytobiol. 2009; 47: 231-6.
12. Furstenberger G, von Moos R, Lucas R, et al Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer. 2006; 94: 524-31.
13. Lastres P, Letamendia A, Zhang H, et al Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol. 1996; 133: 1109-21.
14. Li C, Hampson IN, Hampson L, et al CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J. 2000; 14: 55-64.
15. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med. 2004; 2: 18.
16. Chen H, Ordog T, Chen J, et al Differential gene expression in functional classes of interstitial cells of Cajal in murine small intestine. Physiol Genomics. 2007; 31: 492-509.
17. Mazzone A, Farrugia G. Evolving concepts in the cellular control of gastrointestinal motility: neurogastroenterology and enteric sciences. Gastroenterol Clin North Am. 2007; 36: 499-513.
18. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumours. Virchows Arch. 2010; 456: 111-27.
19. Lux ML, Rubin BP, Biase TL, et al KIT Extracellular and kinase domain mutations in gastrointestinal stromal tumours. Am J Pathol. 2000; 156: 791-5.
20. Isozaki K, Terris B, Belghiti J, et al Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumours. Am J Pathol. 2000; 157: 1581-5.
21. Gromova P, Ralea S, Lefort A, et al Kit K641E oncogene up-regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours. J Cell Mol Med. 2009; 13: 1536-48.
22. Rubin BP, Antonescu CR, Scott-Browne JP, et al A knock-in mouse model of gastrointestinal stromal tumour harboring kit K641E. Cancer Res. 2005; 65: 6631-9.
23. Vanderwinden JM, Wang D, Paternotte N, et al Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT. Cell Signal. 2006; 18: 661-9.
24. Tuveson DA, Willis NA, Jacks T, et al STI571 inactivation of the gastrointestinal stromal tumour c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001; 20: 5054-8.
25. Hellemans J, Mortier G, De Paepe A, et al qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007; 8: R19.
26. Miettinen M, Lasota J. Gastrointestinal stromal tumours: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23: 70-83.
27. Demetri GD, Benjamin RS, Blanke CD, et al NCCN Task Force report: management of patients with gastrointestinal stromal tumour (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007; 5 Suppl 2:S1-29; quiz S30: S1-29.
28. Heinrich MC, Corless CL, Demetri GD, et al Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol. 2003; 21: 4342-9.
29. Greenacre M. Correspondence analysis of raw data. Ecology. 2010; 91: 958-63.
30. Hahm KB, Im YH, Parks TW, et al Loss of transforming growth factor beta signaling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut. 2001; 49: 190-8.
31. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002; 118: 211-5.
32. Vetuschi A, Sferra R, Latella G, et al Smad3-null mice lack interstitial cells of Cajal in the colonic wall. Eur J Clin Invest. 2006; 36: 41-8.
33. Saito K, Sakurai S, Sano T, et al Aberrant methylation status of known methylation-sensitive CpG islands in gastrointestinal stromal tumours without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy. Cancer Sci. 2008; 99: 253-9.
34. House MG, Guo M, Efron DT, et al Tumour suppressor gene hypermethylation as a predictor of gastric stromal tumour behavior. J Gastrointest Surg. 2003; 7: 1004-14.